Amarantus BioSciences, Inc. Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products
Published: Jan 23, 2012
SUNNYVALE, Calif. & THE WOODLANDS, Texas--(BUSINESS WIRE)--Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein being developed for the treatment of Parkinson’s Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. (OTCBB: PWRM) for the NuroPro® Blood Test as it relates to Parkinson’s disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.